Article Per Year (5 Year)
p-Index From 2021 - 2026
2.064
P-Index
This Author published in this journals
All Journal Medula JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Jurnal Pengabdian Kepada Masyarakat (JPKM) Tabikpun Sains Medisina Jurnal Farmasi SYIFA JPM (Jurnal Pengabdian Masyarakat) Ruwa Jurai
Junando, Mirza
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Education Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences Other

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Medula

 1 
Faktor-Faktor yang Mempengaruhi Health Related Quality Of Life (HRQoL) pada Pasien Penyakit Jantung Koroner Tanpa Penyakit Terminal Lubna Farhana; Ramdini, Dwi Aulia; Himayani, Rani; Junando, Mirza
Medula Vol 14 No 4 (2024): Medula
Publisher : CV. Jasa Sukses Abadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53089/medula.v14i4.1045

Abstract

Coronary heart disease (CHD) is a disorder in heart function caused by narrowing of the coronary arteries and atherosclerotic plaque, leading to inadequate oxygen supply to the myocardial muscle. According to the World Health Organization (WHO) data from 2012, CHD is the number 1 cause of death with a percentage of 38.3% of total deaths. Patients with CHD commonly experience symptoms such as chest pain and shortness of breath, which significantly impact in their health-related quality of life (HRQoL). Additionally, complex treatment can also have a broad impact on HRQoL. The aim of this article is to identify the factors influencing HRQoL in CHD patients. In this study, a literature review method was employed, utilizing online databases such as Elsevier, PubMed, Springer. Factors such as social support, comorbidities, lifestyle, disease condition, self-management, and sociodemographic factors are known to influence HRQoL in CHD patients.
Hiperglikemia Pada Terapi Nutrisi Parenteral Dwi Anjani, Galuh; Junando, Mirza; Oktarlina, Rasmi Zakiah; Himayani, Rani
Medula Vol 14 No 4 (2024): Medula
Publisher : CV. Jasa Sukses Abadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53089/medula.v14i4.1050

Abstract

Hyperglycemia is a condition that often occurs in some patients on parenteral nutrition therapy, both with and without a diagnosis of diabetes mellitus. The incidence of hyperglycemia is closely related to an increase in length of stay and mortality in hospital. This literature review aims to provide an overview of the management of hyperglycemia related to parenteral nutrition therapy. The source search method was carried out using the Google Scholar, Pubmed and Elsevier search engines. The keywords used are management of hyperglycemia, risk factors, parenteral nutrition. Based on the results of the literature review, it was found that several factors trigger the incidence of hyperglycemia, including BMI > 25 kg/m2, advanced age, higher HbA1c, history of type 2 DM, use of glucocorticoid drugs and administration of excess carbohydrates and reduced insulin sensitivity. Several strategies to prevent hyperglycemia are carried out by providing low dextrose, hypocaloric parenteral nutrition, or combining parenteral and enteral nutrition. Providing combined nutrition can improve glycemic control in patients with sufficient endogenous insulin stores. Meanwhile, therapeutic measures need to be given if hyperglycemia persists after preventative strategies are implemented. Therapeutic measures that can be taken include administering insulin intravenously or subcutaneously to patients in stable condition. Alternatively, insulin can be added to the parenteral nutrition mixture. It is important to closely monitor blood glucose levels to reduce the risk of hyperglycemia or hypoglycemia.
a Comparison Between Dexamethasone and Prednisolone in ARDS Patients: Literature Review Aqil, Faiq Akhmad; Oktarlina, Rasmi Zakiah; Junando, Mirza; Pardilawati, Citra Yuliyanda
Medula Vol 14 No 8 (2024): Medula
Publisher : CV. Jasa Sukses Abadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53089/medula.v14i8.1275

Abstract

During the COVID-19 pandemic, dexamethasone and methylprednisolone are used to treat COVID-19 patients, particularly those who have acute respiratory distress syndrome (ARDS). Numerous studies have demonstrated that dexamethasone significantly improves respiratory function and lowers mortality in COVID-19 patients, particularly those who need mechanical ventilation. Patients with ARDS with COVID-19 who received dexamethasone had fewer days alive and ventilator-free days, according to a randomized study like the CoDEX trial. But methylprednisolone has also demonstrated encouraging outcomes in treating severe COVID-19 pneumonia, particularly when used as a short-term treatment. The dosage and mode of administration of the two medications differ; dexamethasone is more frequently used to treat the systemic inflammation brought on by this viral infection.
Co-Authors Afriyana, Regi Al Rasyid, Muhammad Irfan Ambarwati, Endah Andrifianie, Femmy Aqil, Faiq Akhmad Asep Sukohar Atri Sri Ulandari Az Zahra, Ghina Nazhifah Cathartica, Allamanda Damayanti, Ervina Dwi Anjani, Galuh Febyolla, Citra Lucky Hakim, Fatiyah Kamilah Lubna Farhana Muhammad Fitra Wardhana Sayoeti Muhammad Iqbal Nikita, Marshanda Nurwijayanti Oktafany, Oktafany Oktoba, Zulpakor Pardilawati, Citra Yuliyanda Putri, Asyifa Adinda Ramadhina, Farrasyifa Ramdini, Dwi Aulia Rani Himayani Rasmi Zakiah Oktarlina Suri, Nurma Thahir, Salsabila Anggraini Tri Umiana Soleha Triyandi, Ramadhan